logo

Evaluation of HBV-DNA Monitoring after Completion of Chemotherapy using a PDCA Cycle following Introduction of a Support System Provided by a Multidisciplinary Team of Quality Management in Cancer Medicine

Authors

  • Satoshi Hibi

    Department of Pharmacy, Nagoya Memorial Hospital, Japan and Quality Management Team in Cancer Medicine, Nagoya Memorial Hospital, Japan

  • Yuko Shirokawa

    Department of Nursing, Nagoya Memorial Hospital, Japan and Quality Management Team in Cancer Medicine, Nagoya Memorial Hospital, Japan

  • Kengo Nanya

    Department of Clinical Laboratory, Nagoya Memorial Hospital, Japan

  • Tatsuya Kawamura

    Department of Clinical Laboratory, Nagoya Memorial Hospital, Japan and Quality Management Team in Cancer Medicine, Nagoya Memorial Hospital, Japan

  • Yuko Kato

    Medical Social Work Consultation Room, Nagoya Memorial Hospital, Japan and Quality Management Team in Cancer Medicine, Nagoya Memorial Hospital, Japan

  • Shu Yuasa

    Department of Pharmacy, Nagoya Memorial Hospital, Japan

  • Satoshi Kayukawa

    Department of Hematology, Nagoya Memorial Hospital, Japan and Quality Management Team in Cancer Medicine, Nagoya Memorial Hospital, Japan

  • Kenji Ina

    Department of Geriatric Medicine, Shinseikai Dai-Ichi Hospital, Nagoya, Japan

DOI:

https://doi.org/10.30683/1929-2279.2025.14.23

Keywords:

PDCA cycle, HBV reactivation, chemotherapy, multidisciplinary team of quality management in cancer medicine, HBV-DNA monitoring

Abstract

Background: Reactivation of the hepatitis B virus (HBV) during or after chemotherapy remains a notable clinical concern, particularly among patients with previous exposure to HBV. However, in clinical practice, adherence to HBV-DNA monitoring after completing chemotherapy is often sub-optimal.

Methods: We developed and implemented a support system based on the plan–do–check–act (PDCA) cycle to ensure 12-month HBV-DNA monitoring after the completion of chemotherapy. This system was designed to enable continuous follow-up after a cessation of chemotherapy, and a multidisciplinary team of quality management in cancer medicine established a feedback system to provide timely information for physicians. Adherence to HBV-DNA monitoring before and after introduction of the system was compared, and the reasons for discontinuation were investigated.

Results: Compared with the pre-intervention group, there was a significant improvement in the rate of HBV-DNA monitoring in the post-intervention group (p < 0.01). In this group, 16 patients (33.3%) were lost to follow-up after chemotherapy due to death or transition to hospice or home-based care.

Conclusions: The support system provided by a multidisciplinary team of quality management in cancer medicine effectively improved adherence to HBV-DNA monitoring after the completion of chemotherapy. However, it also revealed that some patients could not be followed up immediately after the completion of treatment given their deteriorating general condition.

References

[1] Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: A prospective observational study. Clin Infect Dis 2015; 61: 719-29.

[2] Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol 2010; 25(5): 864-71.

[3] Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterol 2017; 152(6): 1297–1309.

[4] Japan Society of Hepatology. Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. Hepatol Res 2020; 50(8): 892-923.

[5] Tanaka Y, Nakamoto D, Piao Y, et al. Implementation of Guideline-Based HBV Reactivation Management in Patients with Chronic HBV Infections of HBsAg or Resolved HBV Infection Undergoing Immunosuppressive Therapy. Infect Dis Ther 2024; 13(7): 1607-1620.

[6] Jang H, Yu SJ, Lee HG, et al. Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study. J Korean Med Sci 2023; 38: e216.

[7] Hibi S, Ina K, Yuasa S, et al. Management of Hepatitis B Virus Reactivation after the Completion of Cancer Chemotherapy using a Plan-do-Check-Act Cycle. Journal of Cancer Research Updates 2022; 11: 78-82.

[8] Takahashi H, Ikeda M, Kumada T, et al. Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents. Hepatol Res 2015; 45(12): 1220-7.

[9] Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 2013; 48(3): 452–458.

[10] Yazaki S, Yamauchi T, Higashi T. High hepatitis B virus screening rate among patients receiving systemic anticancer treatment in Japan. Int J Clin Oncol 2020; 25(7): 1327-1333.

[11] Kusumoto S, Tanaka Y, Ueda R, et al. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol 2011; 46(1): 9-16.

[12] Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011; 22(5): 1170-1180.

[13] Fatma C, Seda Y, Mustafa D. Evaluation of the clinical practices and awareness of hematologists related to hepatitis B reactivation. Ann Med Res 2022; 29(2): 153–158.

Downloads

Published

2025-12-09

Issue

Vol. 14 (2025)

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Evaluation of HBV-DNA Monitoring after Completion of Chemotherapy using a PDCA Cycle following Introduction of a Support System Provided by a Multidisciplinary Team of Quality Management in Cancer Medicine. (2025). Journal of Cancer Research Updates, 14, 218-223. https://doi.org/10.30683/1929-2279.2025.14.23

Similar Articles

1-10 of 223

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)